<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 70 - Mims</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page69.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../index.html#p=70">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 70 - Mims</div>
        <div id="content-top2">P. 70</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../index.html#p=70"><img src="../thumb/70.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>60     TreaTmenT approaches



          until the ua level is below 0.4 mmol/l. Patients   AsympTomATic hyperuricAemiA
          intolerant to colchicine can be offered low-dose   the management  of asymptomatic hyper-
          nSaIds, unless contraindicated, to use should an   uricaemia is controversial. Currently,  ult is not
          attack occur while initiating ult. 12   advised for its management. However there
            Importantly, should an acute attack occur,   may be advantages in treating asymptomatic
          allopurinol  should not  be  stopped, but rather   hyperuricaemia in patients with chronic kidney
          continued alongside the treatment for the acute   disease and in the setting of patients post acute
          attack. Patients and their healthcare providers   myocardial infarction. Further studies are needed
          need to be educated about this principle, because   to form future management guidelines. 14,8
          otherwise a vicious cycle of acute attack, initiation
          of ult, new attack, discontinuation of ult, recurrent   goAl of gouT TherApy
          attack ensues with little progress made to prevent   the goal for all patients with gout is to achieve
          future attacks by lowering ua levels.    a serum  ua level of 0.36 mmol/l,  with a  lower
            the  dose of allopurinol  should be  titrated   goal (0.30 mmol/l) for patients with severe/
                                                               10
          upwards every two to five weeks.  recent data   tophaceous gout.  Patients can be reassured that
          have shown that allopurinol at a dose of ≤300 mg   it is possible for attacks to stop and for tophi to
          daily fails to achieve an appropriate reduction in   resolve with effective treatment.
          serum ua levels in approximately 30-50% of gout   REfEREncEs
          patients with normal renal function.  a treat-to-  1.   ragab G,  elshahaly M,  bardin  t. Gout:  an old
                                    14
          target strategy is suggested where allopurinol   disease in new perspective – a review.  J Adv Res.
          is increased until a target serum  ua level of   2017;8(5):495-511.
          0,36  mmol/l, or 0.30 in patients with tophi, is   2.   dalbeth  n, Merriman tr, Stamp  lK. Gout.  Lancet.
          reached. allopurinol can be prescribed in doses   2016;388(10055):2039-52.2.
          up to 800 mg daily.                     3.   Mandal aK, Mount db. the molecular physiology of
            Febuxostat is an alternative XoI with a much   uric acid homeostasis. Ann Rev Physiol. 2015;77:323-45.
          lower risk of hypersensitivity reactions, but is   4.   beyl  rn Jr, Hughes  l, Morgan S.  update
          expensive, not yet available in South  africa   on  importance  of  diet  in  gout.  Am J Med.
                                                     2016;129(11):1153-8.
          and may be associated with increased risk of   5.   Klippel  J,  et  al.  Primer  on  the  Rheumatic  Diseases.
          cardiovascular events.                     berlin: Springer Science & business Media; 2001.
                                                  6.   neogi t, et al. 2015 Gout classification criteria: an
          Uricosurics                                american College of  rheumatology/european
          Probenecid can be used in the management of   league against rheumatism collaborative initiative.
          chronic gout, including combination therapy   Ann Rheum Dis. 2015;74(10):1789-98.
          with XoI. It is contraindicated in patients with   7.   abrahams Mn. Gout and hyperuricaemia.  South
                                                     African Medical Journal. 2015;105(12).
          a history of urolithiasis, patients who produce   8.   Krishnan e, et al. Hyperuricemia and untreated gout
          excess ua and those who have renal failure with   are poor prognostic markers among those with a
          an eGFr &lt;50 ml/min.  Pegloticase is a pegylated   recent acute myocardial infarction. Arthritis Res Ther.
                         13,5
          uricase employed in the management of severe   2012;14(1)r10.
          refractory gout and can be used in patients with   9.   van echteld I, et al. Colchicine for acute gout. Cochrane
          renal impairment. Its use is limited due to its cost.  Database Syst Rev. 2014 august;(8)Cd006190.
                                                  10.   richette  P,  et al. 2016 updated  eular evidence-
          concomitant medication                     based recommendations for the management of
                                                     gout. Ann Rheum Dis. 2017;76(1):29-42.
          Where possible, drugs that cause hyperuricaemia   11.   Hill eM, Sky K, Sit M, et al. does starting allopurinol
          should be reviewed and discontinued. However,   prolong acute treated gout? a randomized clinical
          low-dose aspirin for cardio-protection should not   trial. J Clin Rheumatol. 2015;21:120-5.
          be stopped; diuretics may be difficult to withdraw   12.   nuki G, doherty M, richette P. Current management
          in heart failure or renal insufficiency and should   of gout: Practical messages from 2016  eular
          be prescribed continuously at the lowest dose   guidelines. Polish Arch Intern Med. 2017;127(4):267-77.
          possible, because intermittent use of diuretics can   13.   Khanna  d,  et al.  2012  american College  of
          precipitate gout flares. drugs with mild uricosuric   rheumatology  guidelines  for  management
                                                     of gout. Part 1: Systematic nonpharmacologic
          action  include losartan (angiotensin receptor   and pharmacologic therapeutic approaches to
          blocker), amlodipine (calcium-channel blocker),   hyperuricemia. Arthritis Care Res. 2012;64(10):1431-46.
          statins and fenofibrates, and should be prescribed   14.   Jalal dI, et al. uric acid as a target of therapy in CKd.
          where possible.                            Am J Kidney Dis. 2013;61(1):134-46.


          MIMS ConCISe GuIde to CardIovaSCular, MetabolIC and endoCrIne dISeaSeS  VOLUME 1</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page69.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page65.html">65</a>&nbsp;&nbsp;&nbsp;<a href="page66.html">66</a>&nbsp;&nbsp;&nbsp;<a href="page67.html">67</a>&nbsp;&nbsp;&nbsp;<a href="page68.html">68</a>&nbsp;&nbsp;&nbsp;<a href="page69.html">69</a>&nbsp;&nbsp;&nbsp;<a href="page70.html">70</a>&nbsp;&nbsp;&nbsp;<a href="page71.html">71</a>&nbsp;&nbsp;&nbsp;<a href="page72.html">72</a>&nbsp;&nbsp;&nbsp;<a href="page73.html">73</a>&nbsp;&nbsp;&nbsp;<a href="page74.html">74</a>&nbsp;&nbsp;&nbsp;<a href="page75.html">75</a>
             </td>
             <td width="35%"><a href="page71.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page71.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
